چكيده انگليسي :
Insufficient oxygenation in body tissues, known as hypoxia, can disrupt bodily functions and metabolism. Conversely, adequate oxygen levels facilitate healing and effective treatment for certain diseases and wounds. Consequently, recent research has focused on oxygen and oxygen-releasing substances. Among these substances are solid peroxides, hydrogen peroxide carriers, sodium percarbonate, and fluorinated compounds, which have been investigated extensively. Additionally, polymer nanofibers have garnered significant attention for their desirable properties such as a high surface-to-volume ratio, high porosity, fine pores, and suitable mechanical properties, making them ideal for wound dressing applications. Combining oxygen-releasing substances with nanofibers can potentially enhance wound treatment synergistically. To advance this research, calcium peroxide (CP) particles were synthesized and characterized. Eudragit RS100 nanofibers were then produced with varying concentrations of these particles (ranging from 0.3% to 9%w/v), while Eudragit L100 nanofibers were prepared containing 5% wt of ciprofloxacin hydrochloride (CH) drug. Viscosity assessments revealed that the addition of CH drug to Eudragit L100 solution did not induce significant changes in viscosity. However, for Eudragit RS100 solution, the incorporation of 4% CP particles resulted in a substantial increase in viscosity, rising from 845.8 to 2405.0 centipoise. Microscopic analysis revealed the uniform distribution of CP particles on Eudragit RS100 nanofibers. The addition of 5% CH drug resulted in an increase in the average diameter of Eudragit L100 nanofibers from 763 to 849 nm. Moreover, the incorporation of 4% CP particles led to a significant diameter increase in Eudragit RS100 nanofibers, with the average diameter changing from 482 to 674 nm. The maximum oxygen released increased from 0.33 mg/g.membrane in the sample with 0.3% CP particles to an impressive 3.67 mg/g.membrane in the 4% concentration. However, beyond this threshold, no significant increase in oxygen release was noted. The drug release mechanism from Edrajet L100 nanofibers, loaded with medication, undergoes distinct behaviors depending on the pH environment. At pH 5, simulating conditions akin to healthy skin, the release pattern follows a Fickian diffusion model, with the governing kinetic mechanism aligning with the Higuchi model. However, in a pH 7.4 environment mimicking infected skin, the release mechanism shifts to a non-Fickian pattern, indicating a more complex diffusion process. The governing kinetic model transitions to a first-order release, showing intelligent drug release behavior. Further research led to the development of a hybrid nanofibrous layer comprising Eudragit L100 nanofibers with drugs and Eudragit RS100 nanofibers with CP particles. The findings revealed a bimodal diameter distribution among the nanofibers, showcasing two prominent peaks at 600 and 800 nm. This distinctive pattern is likely due to the composition differences between Edragit nanofibers RS100, which incorporates CP particles, contribute to the first peak, while those of L100, imbued with drugs, contribute to the latter. The hybrid layer exhibited an oxygen release of 3.86 mg/g.memberan which primarily attributed to Edrajet RS100 nanofibers containing the CP particles. The drug release mechanism and kinetic model observed in this hybrid nanofibrous layer closely resembled that of Edrajet L100 nanofibers containing the drug. Moreover, this nanofibrous layer demonstrated intelligent drug release behavior. The hybrid nanofibrous layer exhibits water absorption, water vapor, and air permeability at rates of 150%, 35.709 mg/cm²·h, and 4.067 ml/s·cm², respectively. These metrics closely align with those observed for Eudragit RS100 nanofibers, indicating their significant influence within the hybrid layer's structure.
